دورية أكاديمية
أعرض في EDS

Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolution.

التفاصيل البيبلوغرافية
العنوان: Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolution.
المؤلفون: Dietzen M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Zhai H; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Lucas O; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.; Department of Oncology, University College London Hospitals, London, UK., Pich O; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Barrington C; Bioinformatics and Biostatistics Science Technology Platform, The Francis Crick Institute, London, UK., Lu WT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Ward S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Guo Y; CRUK Flow Cytometry Translational Technology Platform, UCL Cancer Institute, London, UK., Hynds RE; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Zaccaria S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK., Swanton C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Department of Oncology, University College London Hospitals, London, UK., McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. n.kanu@ucl.ac.uk.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. n.kanu@ucl.ac.uk.
المصدر: Nature communications [Nat Commun] 2024 Jul 18; Vol. 15 (1), pp. 6039. Date of Electronic Publication: 2024 Jul 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Mutation* , DNA Replication Timing*, Humans ; Female ; Cell Line, Tumor ; APOBEC Deaminases/genetics ; APOBEC Deaminases/metabolism ; Mutation Rate ; DNA Replication/genetics ; Genome, Human
مستخلص: During each cell cycle, the process of DNA replication timing is tightly regulated to ensure the accurate duplication of the genome. The extent and significance of alterations in this process during malignant transformation have not been extensively explored. Here, we assess the impact of altered replication timing (ART) on cancer evolution by analysing replication-timing sequencing of cancer and normal cell lines and 952 whole-genome sequenced lung and breast tumours. We find that 6%-18% of the cancer genome exhibits ART, with regions with a change from early to late replication displaying an increased mutation rate and distinct mutational signatures. Whereas regions changing from late to early replication contain genes with increased expression and present a preponderance of APOBEC3-mediated mutation clusters and associated driver mutations. We demonstrate that ART occurs relatively early during cancer evolution and that ART may have a stronger correlation with mutation acquisition than alterations in chromatin structure.
(© 2024. The Author(s).)
References: Nature. 2020 Feb;578(7793):112-121. (PMID: 32025012)
Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926)
Cancer Cell. 2017 Dec 11;32(6):884. (PMID: 29232558)
Cell. 2018 Aug 9;174(4):1034-1035. (PMID: 30096302)
Nat Biotechnol. 2017 Apr 11;35(4):316-319. (PMID: 28398311)
Genes (Basel). 2020 Mar 19;11(3):. (PMID: 32204553)
Nat Commun. 2019 Jan 24;10(1):416. (PMID: 30679435)
Science. 2022 Apr 22;376(6591):. (PMID: 35949260)
Nat Clin Pract Oncol. 2007 Sep;4(9):516-25. (PMID: 17728710)
Nat Genet. 2013 Sep;45(9):970-6. (PMID: 23852170)
Blood Adv. 2019 Nov 12;3(21):3201-3213. (PMID: 31698451)
Exp Hematol. 2017 Jul;51:71-82.e3. (PMID: 28433605)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
Cell. 2018 Jun 14;173(7):1823. (PMID: 29906452)
Nat Protoc. 2011 Jun;6(6):870-95. (PMID: 21637205)
Nat Commun. 2016 May 02;7:11383. (PMID: 27136393)
Cold Spring Harb Perspect Biol. 2013 Aug 01;5(8):a010132. (PMID: 23838440)
Nat Genet. 2020 Nov;52(11):1178-1188. (PMID: 33020667)
Nat Rev Cancer. 2018 Nov;18(11):696-705. (PMID: 30293088)
N Engl J Med. 2017 Jun 1;376(22):2109-2121. (PMID: 28445112)
F1000Res. 2020 Jan 29;9:63. (PMID: 32269765)
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. (PMID: 20837533)
Nat Biotechnol. 2011 Nov 20;29(12):1103-8. (PMID: 22101487)
Sci Transl Med. 2015 Apr 15;7(283):283ra54. (PMID: 25877892)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
BMC Bioinformatics. 2017 Aug 7;18(1):362. (PMID: 28784090)
Cell. 2014 Nov 20;159(5):1015-1026. (PMID: 25416942)
Genome Biol. 2018 Sep 10;19(1):129. (PMID: 30201020)
Sci Rep. 2023 May 15;13(1):7833. (PMID: 37188696)
Nat Genet. 2009 Apr;41(4):393-5. (PMID: 19287383)
Nature. 2023 Apr;616(7957):525-533. (PMID: 37046096)
DNA Repair (Amst). 2019 Sep;81:102647. (PMID: 31307927)
Nat Genet. 2020 Sep;52(9):958-968. (PMID: 32747826)
Science. 2016 Nov 4;354(6312):618-622. (PMID: 27811275)
Nature. 2014 Nov 20;515(7527):402-5. (PMID: 25409831)
CSH Protoc. 2006 Jun 01;2006(1):. (PMID: 22485786)
J Mol Biol. 2013 Nov 29;425(23):4690-5. (PMID: 23603017)
PLoS Genet. 2021 Mar 25;17(3):e1009467. (PMID: 33764973)
Bioinformatics. 2013 Aug 15;29(16):2041-3. (PMID: 23736529)
Nat Protoc. 2018 May;13(5):819-839. (PMID: 29599440)
Nat Commun. 2020 Jul 29;11(1):3696. (PMID: 32728046)
Nat Commun. 2023 Jun 6;14(1):3303. (PMID: 37280210)
Int J Cancer. 2018 Jul 1;143(1):160-166. (PMID: 29569246)
Biostatistics. 2010 Jan;11(1):164-75. (PMID: 19837654)
J Mol Biol. 2014 Oct 9;426(20):3330-41. (PMID: 24905010)
Am J Respir Cell Mol Biol. 2008 Nov;39(5):591-7. (PMID: 18539954)
Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616)
Nat Commun. 2018 Jan 30;9(1):427. (PMID: 29382831)
Genome Res. 2010 Jun;20(6):761-70. (PMID: 20430782)
Cancer Res. 2021 Dec 15;81(24):6106-6116. (PMID: 34702725)
Nucleic Acids Res. 2016 May 19;44(9):4222-32. (PMID: 27085808)
J Cell Biol. 2017 Jul 3;216(7):1907-1914. (PMID: 28539386)
Nat Commun. 2013;4:1502. (PMID: 23422670)
Sci Rep. 2019 Jun 27;9(1):9354. (PMID: 31249361)
Genome Res. 2018 Jun;28(6):800-811. (PMID: 29735606)
Cancer Res. 2004 Dec 15;64(24):9027-34. (PMID: 15604268)
Am J Hum Genet. 2012 Dec 7;91(6):1033-40. (PMID: 23176822)
Nucleic Acids Res. 2020 Jan 8;48(D1):D882-D889. (PMID: 31713622)
Nat Commun. 2021 Feb 15;12(1):1035. (PMID: 33589603)
Nat Rev Genet. 2015 Apr;16(4):213-23. (PMID: 25732611)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Nat Rev Cancer. 2020 Oct;20(10):555-572. (PMID: 32778778)
Nature. 2020 Nov;587(7832):126-132. (PMID: 32879494)
Science. 2022 Sep 16;377(6612):eabj5502. (PMID: 36108018)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
Front Microbiol. 2014 Oct 13;5:534. (PMID: 25352838)
Mol Oncol. 2010 Oct;4(5):397-403. (PMID: 20594926)
Genome Res. 2017 Aug;27(8):1406-1416. (PMID: 28512193)
Nature. 2015 Feb 19;518(7539):360-364. (PMID: 25693567)
Nat Genet. 2013 Sep;45(9):977-83. (PMID: 23852168)
Bioinformatics. 2012 Jul 15;28(14):1811-7. (PMID: 22581179)
Bioinformatics. 2010 Mar 15;26(6):841-2. (PMID: 20110278)
Cell. 2012 May 25;149(5):994-1007. (PMID: 22608083)
Genome Res. 2012 Oct;22(10):1833-44. (PMID: 22628462)
Nat Commun. 2012;3:1004. (PMID: 22893128)
Nature. 2015 May 7;521(7550):81-4. (PMID: 25707793)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; FC001169 United Kingdom ARC_ Arthritis Research UK
المشرفين على المادة: EC 3.5.4.5 (APOBEC Deaminases)
EC 3.5.4.5 (APOBEC3 proteins, human)
تواريخ الأحداث: Date Created: 20240717 Date Completed: 20240717 Latest Revision: 20240720
رمز التحديث: 20240720
مُعرف محوري في PubMed: PMC11255325
DOI: 10.1038/s41467-024-50107-4
PMID: 39019871
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-50107-4